OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Respiratory and Critical Care Medicine is 85. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress Syndrome	1015
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline	853
Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study	629
COVID-19 with Different Severities: A Multicenter Study of Clinical Features	595
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline	511
Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2	475
Characterization of the Inflammatory Response to Severe COVID-19 Illness	447
Why COVID-19 Silent Hypoxemia Is Baffling to Physicians	419
Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease	417
Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19	373
COVID-19–related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids	325
Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study	319
Endothelial Responses in Sepsis	297
A Single-Cell Atlas of the Human Healthy Airways	290
COVID-19–associated Pulmonary Aspergillosis	269
Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2	260
Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2	250
Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis	233
Tissue-Specific Immunopathology in Fatal COVID-19	232
Pulmonary Angiopathy in Severe COVID-19: Physiologic, Imaging, and Hematologic Observations	225
Lung Recruitability in COVID-19–associated Acute Respiratory Distress Syndrome: A Single-Center Observational Study	217
Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis	205
Basing Respiratory Management of COVID-19 on Physiological Principles	205
Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline	200
Hospital Preparedness for COVID-19: A Practical Guide from a Critical Care Perspective	200

Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes	196
Expression of the SARS-CoV-2 ACE2 Receptor in the Human Airway Epithelium	189
Symptoms of Anxiety, Depression, and Peritraumatic Dissociation in Critical Care Clinicians Managing Patients with COVID-19. A Cross-Sectional Study	186
High-Flow Nasal Cannula in Critically III Patients with Severe COVID-19	176
Lung- and Diaphragm-Protective Ventilation	168
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study	163
SARS-CoV-2 Viral Load in Clinical Samples from Critically Ill Patients	161
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial	155
Early Inspiratory Effort Assessment by Esophageal Manometry Predicts Noninvasive Ventilation Outcome in De Novo Respiratory Failure. A Pilot Study	155
Ventilatory Variables and Mechanical Power in Patients with Acute Respiratory Distress Syndrome	154
Mechanical Ventilation in COVID-19: Interpreting the Current Epidemiology	153
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele	152
Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome	151
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease	146
Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease	142
Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications	141
The Structural and Social Determinants of the Racial/Ethnic Disparities in the U.S. COVID-19 Pandemic. What’s Our Role?	137
Air Pollution, Genetic Factors, and the Risk of Lung Cancer: A Prospective Study in the UK Biobank	137
Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline	131
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary	131
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study	130
Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline	128
Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids	127
An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal	126
Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection	126
Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU	125
Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society Statement	124
From GOLD 0 to Pre-COPD	119
Effect of Lowering Vt on Mortality in Acute Respiratory Distress Syndrome Varies with Respiratory System Elastance	116
Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision	115
Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical	114
Respiratory Mechanics of COVID-19– versus Non–COVID-19–associated Acute Respiratory Distress Syndrome	113
Ineffectual Type 2–to–Type 1 Alveolar Epithelial Cell Differentiation in Idiopathic Pulmonary Fibrosis: Persistence of the KRT8^hi Transitional State	112
Secretory Cells Dominate Airway CFTR Expression and Function in Human Airway Superficial Epithelia	111
Sleep Apnea–Specific Hypoxic Burden, Symptom Subtypes, and Risk of Cardiovascular Events and All-Cause Mortality	111
Aerosol Generation from the Respiratory Tract with Various Modes of Oxygen Delivery	110
Inflammatory Endotype–associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis	109
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis	105
Machine Learning Classifier Models Can Identify Acute Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data	104
Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case–Control Study	103
Assessing the Accuracy of a Deep Learning Method to Risk Stratify Indeterminate Pulmonary Nodules	103
Single-Cell Reconstruction of Human Basal Cell Diversity in Normal and Idiopathic Pulmonary Fibrosis Lungs	102
Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency	101
Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia	100
Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial	98
Trends in Intensive Care for Patients with COVID-19 in England, Wales, and Northern Ireland	96
Mitigating Inequities and Saving Lives with ICU Triage during the COVID-19 Pandemic	95
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension	95
The Early Change in Pa_CO₂after Extracorporeal Membrane Oxygenation Initiation Is Associated with Neurological Complications	95
New Physical, Mental, and Cognitive Problems 1 Year after ICU Admission: A Prospective Multicenter Study	94

Injury to the Endothelial Glycocalyx in Critically Ill Patients with COVID-19	94
The Epidemiological Importance of Subclinical Tuberculosis. A Critical Reappraisal	92
The Sleep Apnea–Specific Pulse-Rate Response Predicts Cardiovascular Morbidity and Mortality	91
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled T	91
High Prevalence of Pulmonary Sequelae at 3 Months after Hospital Discharge in Mechanically Ventilated Survivors of COVID-19	90
Characterization of Disease Phenotype in Very Preterm Infants with Severe Bronchopulmonary Dysplasia	90
Airway Occlusion Pressure As an Estimate of Respiratory Drive and Inspiratory Effort during Assisted Ventilation	90
Necroptosis Signaling Promotes Inflammation, Airway Remodeling, and Emphysema in Chronic Obstructive Pulmonary Disease	89
Sleep Apnea and COVID-19 Mortality and Hospitalization	88
ACE2 Elevation in Severe COVID-19	87